European Heart Journal Advance Access published online on March 7, 2006
European Heart Journal, doi:10.1093/eurheartj/ehi815
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Children's Heart Centre, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
* To whom correspondence should be addressed. Aims Periconceptional folate supplementation prevents neural tube defects and possibly congenital heart defects (CHD) as well. The search for candidate genes involved in the folate metabolism includes the methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism. We studied the association between MTHFR 677C>T variants and CHD risk. The interaction with periconceptional folate supplementation was also investigated. Methods and results A case-control study and a family-based transmission disequilibrium test (TDT) were conducted to explore this association. In 133 triads, the TDT revealed no association of the fetal 677T allele with the development of a heart defect. In 158 mothers with a CHD-affected child, the maternal MTHFR 677CT and TT genotypes in combination with no use of periconceptional folate supplements were associated with, respectively, a three-fold (OR 3.3 95% CI 1.46-7.32) and six-fold (OR 6.3 95% CI 2.32-17.27) increased risk for conotruncal heart defects in offspring. In a case-only study, the interaction between periconceptional folate supplementation and maternal MTHFR genotype was significant (P = 0.012). Conclusion The maternal MTHFR 677C>T variants are a risk factor for CHD in offspring, confined to conotruncal heart defects. A gene-environment interaction between maternal MTFHR 677CT and TT genotypes with periconceptional folate supplementation was observed. These findings provide a mechanism of the protective role of folate and support the thesis that periconceptional folate supplementation might prevent CHD.
Received July 19, 2005
Revised December 10, 2005
Accepted February 9, 2006
Clinical research
Maternal MTHFR 677C>T is a risk factor for congenital heart defects: effect modification by periconceptional folate supplementation
Ingrid M. van Beynum 1 *,
Livia Kapusta 1,
Martin den Heijer 2,
Sita H.H.M. Vermeulen 3,
Margreet Kouwenberg 4,
Otto Daniëls 1,
and
Henk J. Blom 5
2 Department of Endocrinology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands; Department of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
3 Department of Endocrinology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
4 Department of Pediatrics, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
5 Laboratory of Pediatrics and Neurology, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands
Ingrid M. van Beynum, E-mail: i.vanbeynum{at}cukz.umcn.nl
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. Ionescu-Ittu, A. J Marelli, A. S Mackie, and L. Pilote Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada BMJ, May 12, 2009; 338(may12_2): b1673 - b1673. [Abstract] [Full Text] [PDF] |
||||
![]() |
I.M. van Beynum, M. den Heijer, H.J. Blom, and L. Kapusta The MTHFR 677C->T polymorphism and the risk of congenital heart defects: a literature review and meta-analysis QJM, December 1, 2007; 100(12): 743 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Jongbloet Non-optimal maturation of the oocyte, maternal MTHFR polymorphisms, periconceptional folate, and decrease of congenital heart defects Eur. Heart J., August 2, 2007; 28(16): 2043 - 2043. [Full Text] [PDF] |
||||


